Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Capital Leases (2019 - 2026)

Orthofix Medical has reported Capital Leases over the past 8 years, most recently at $12.9 million for Q1 2026.

  • For the quarter ending Q1 2026, Capital Leases fell 26.64% year-over-year to $12.9 million, compared with a TTM value of $12.9 million through Mar 2026, down 26.64%, and an annual FY2025 reading of $17.1 million, down 4.35% over the prior year.
  • Capital Leases came in at $12.9 million for Q1 2026, down from $17.1 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $19.7 million in Q1 2022 to a low of $12.9 million in Q1 2026.
  • Median Capital Leases over the past 5 years was $18.3 million (2024), compared with a mean of $18.1 million.
  • The sharpest move saw Capital Leases dropped 2.73% in 2022, then fell 26.64% in 2026.
  • Over 5 years, Capital Leases stood at $19.2 million in 2022, then decreased by 3.67% to $18.5 million in 2023, then fell by 3.76% to $17.8 million in 2024, then fell by 4.35% to $17.1 million in 2025, then fell by 24.17% to $12.9 million in 2026.
  • Per Business Quant, the three most recent readings for OFIX's Capital Leases are $12.9 million (Q1 2026), $17.1 million (Q4 2025), and $17.2 million (Q3 2025).